Since the US Food and Drug Administration (FDA) announced recently its revocation of Avastin® (bevacizumab) as a treatment for metastatic breast cancer, Roche has confirmed that it will continue its research with the drug. Phase III studies will test the drug in combination with paclitaxel for MBC patients as a first line of treatment. In addition, Roche will also conduct studies to determine the biomarker/s for the subgroup of patients who are exceptionally receptive to treatment with Avastin.
5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.